Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 185

1.

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P.

J Diabetes Complications. 2018 Sep 13. pii: S1056-8727(18)30811-0. doi: 10.1016/j.jdiacomp.2018.09.005. [Epub ahead of print]

PMID:
30318163
2.

C3 Glomerulopathy: A New Disease Comes of Age.

Appel GB.

Mayo Clin Proc. 2018 Aug;93(8):968-969. doi: 10.1016/j.mayocp.2018.06.014. No abstract available.

PMID:
30077212
3.

UBD modifies APOL1-induced kidney disease risk.

Zhang JY, Wang M, Tian L, Genovese G, Yan P, Wilson JG, Thadhani R, Mottl AK, Appel GB, Bick AG, Sampson MG, Alper SL, Friedman DJ, Pollak MR.

Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):3446-3451. doi: 10.1073/pnas.1716113115. Epub 2018 Mar 12.

4.

Treatment of Rapidly Progressive Glomerulonephritis in the Elderly.

Appel GB, Lau WL.

Blood Purif. 2018;45(1-3):208-212. doi: 10.1159/000485367. Epub 2018 Jan 26.

5.

Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.

Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, Li Y, Gharavi AG, Appel GB.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):406-413. doi: 10.2215/CJN.09080817. Epub 2018 Jan 11.

PMID:
29326307
6.

C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.

Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB.

Kidney Int. 2018 Apr;93(4):977-985. doi: 10.1016/j.kint.2017.10.022. Epub 2018 Jan 6.

PMID:
29310824
7.

Whole-Exome Sequencing in Adults With Chronic Kidney Disease: A Pilot Study.

Lata S, Marasa M, Li Y, Fasel DA, Groopman E, Jobanputra V, Rasouly H, Mitrotti A, Westland R, Verbitsky M, Nestor J, Slater LM, D'Agati V, Zaniew M, Materna-Kiryluk A, Lugani F, Caridi G, Rampoldi L, Mattoo A, Newton CA, Rao MK, Radhakrishnan J, Ahn W, Canetta PA, Bomback AS, Appel GB, Antignac C, Markowitz GS, Garcia CK, Kiryluk K, Sanna-Cherchi S, Gharavi AG.

Ann Intern Med. 2018 Jan 16;168(2):100-109. doi: 10.7326/M17-1319. Epub 2017 Dec 5.

8.

Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies.

Mariani LH, Martini S, Barisoni L, Canetta PA, Troost JP, Hodgin JB, Palmer M, Rosenberg AZ, Lemley KV, Chien HP, Zee J, Smith A, Appel GB, Trachtman H, Hewitt SM, Kretzler M, Bagnasco SM.

Nephrol Dial Transplant. 2018 Feb 1;33(2):310-318. doi: 10.1093/ndt/gfw443.

PMID:
28339906
9.

A proposal for standardized grading of chronic changes in native kidney biopsy specimens.

Sethi S, D'Agati VD, Nast CC, Fogo AB, De Vriese AS, Markowitz GS, Glassock RJ, Fervenza FC, Seshan SV, Rule A, Racusen LC, Radhakrishnan J, Winearls CG, Appel GB, Bajema IM, Chang A, Colvin RB, Cook HT, Hariharan S, Herrera Hernandez LP, Kambham N, Mengel M, Nath KA, Rennke HG, Ronco P, Rovin BH, Haas M.

Kidney Int. 2017 Apr;91(4):787-789. doi: 10.1016/j.kint.2017.01.002.

PMID:
28314581
10.

Thrombotic microangiopathies: Similar presentations, different therapies.

Appel GB.

Cleve Clin J Med. 2017 Feb;84(2):114-130. doi: 10.3949/ccjm.84gr.17001. Review.

11.

Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents.

Avasare RS, Rosenstiel PE, Zaky ZS, Tsapepas DS, Appel GB, Markowitz GS, Bomback AS, Canetta PA.

Am J Nephrol. 2017;45(2):99-106. doi: 10.1159/000453081. Epub 2017 Jan 6.

12.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.

J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.

13.

The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.

Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, Gipson DS, Kretzler M, Troost JP, Lieske JC.

Kidney Int. 2016 Nov;90(5):1080-1089. doi: 10.1016/j.kint.2016.06.020. Epub 2016 Aug 12.

14.

Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways.

Bomback AS, Markowitz GS, Appel GB.

Kidney Int Rep. 2016 Jul 1;1(3):148-155. doi: 10.1016/j.ekir.2016.06.005. eCollection 2016 Sep. Review.

15.

Filgrastim-Induced Crescentic Transformation of Recurrent IgG2λ GN.

Batal I, Markowitz GS, Wong W, Avasare R, Mapara MY, Appel GB, D'Agati VD.

J Am Soc Nephrol. 2016 Jul;27(7):1911-5. doi: 10.1681/ASN.2016010061. Epub 2016 May 4.

16.

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.

Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, Katafuchi R, Appel GB, Maes BD, Li PK, Praga M, Del Vecchio L, Andrulli S, Manno C, Gutierrez E, Mercer A, Carroll KJ, Schmid CH, Levey AS.

Am J Kidney Dis. 2016 Sep;68(3):392-401. doi: 10.1053/j.ajkd.2016.02.042. Epub 2016 Mar 29.

PMID:
27032886
17.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

18.

Therapy: New data do not support use of abatacept in diabetic nephropathy.

Appel GB.

Nat Rev Nephrol. 2015 Dec;11(12):692-4. doi: 10.1038/nrneph.2015.178. Epub 2015 Nov 16. No abstract available.

PMID:
26568189
19.

Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, Jennette JC, Bajema IM, Alpers CE, Chang A, Cornell LD, Cosio FG, Fogo AB, Glassock RJ, Hariharan S, Kambham N, Lager DJ, Leung N, Mengel M, Nath KA, Roberts IS, Rovin BH, Seshan SV, Smith RJ, Walker PD, Winearls CG, Appel GB, Alexander MP, Cattran DC, Casado CA, Cook HT, De Vriese AS, Radhakrishnan J, Racusen LC, Ronco P, Fervenza FC.

J Am Soc Nephrol. 2016 May;27(5):1278-87. doi: 10.1681/ASN.2015060612. Epub 2015 Nov 13.

20.

New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.

Magistroni R, D'Agati VD, Appel GB, Kiryluk K.

Kidney Int. 2015 Nov;88(5):974-89. doi: 10.1038/ki.2015.252. Epub 2015 Sep 16. Review.

Supplemental Content

Loading ...
Support Center